August 24, 2012

WEEKLY MARKET DIGEST: HOPE IS NEVER A GOOD INVESTMENT STRATEGY

(The Weekly Digest reproduces the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers.)

DURABLE GOODS ORDERS PLUNGE

August 24, 2012

Durable Goods Orders ex-transports came at -0.4% compared to consensus of +0.6%.

Gold futures are at $1666, silver futures are at $30.39, and oil futures are $95.85.

S&P 500 resistance levels are 1400, 1410, and 1415; support levels are 1380, 1368, and 1358.

DJIA futures are down 22 points.

GOLD SPIKES AGAIN ON CHINA PMI

August 23, 2012

China flash HSBC PMI fell to 47.8 in August from a final 49.3 in July.… Please click here or the title below to read more.

August 24, 2012

TAKE PROFITS AND EXIT LLY

This post was published on ZYX Short Sell Change Alert

Consider taking profits and exiting LLY trade right here around $43.60. We will provide more details over the weekend.… Please click here or the title below to read more.

August 24, 2012

TAKE PARTIAL PROFITS ON LLY

This post was published on ZYX Short Sell Change Alert

Consider taking profits on the last tranche from around $46 right here $43.40- 43.65. THis will leave 20% still held.… Please click here or the title below to read more.

August 24, 2012

CAUTION ON LLY

This post was published on ZYX Short Sell Change Alert

We are repeating that conservative investors should not enter this trade. Even though the trial has failed and there is not enough life left in the patent, the disease evokes such emotion the some will continue to run up the stock. The situation can cause big draw downs. Therefore the trade is not suitable for those who may have difficulty handling a big draw down.… Please click here or the title below to read more.

August 24, 2012

ADD TO LLY

This post was published on ZYX Short Sell Change Alert

Consider adding another 10% tranche in the zone of $45.90 to $46.60.… Please click here or the title below to read more.

August 24, 2012

DETAILS ON LLY TRIAL

This post was published on ZYX Short Sell Change Alert

The stock is likely to be very volatile, conservative investors should not enter this trade. The results of the trial are being misinterpreted by some in the market. Here are the details.

LLY announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer’s disease. However, a pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer’s disease.… Please click here or the title below to read more.

August 24, 2012

MORE ON LLY

This post was published on ZYX Short Sell Change Alert

Stock moved right after the post. Most fills should be $43.87. Consider adding 10% around $43.80-44.50.… Please click here or the title below to read more.

August 24, 2012